Our Disease Models are based on 3D InSight™ Human Liver Microtissue technology and include specially formulated media and cocktails to induce the desired disease state in healthy liver organoids. They incorporate all the primary human liver cells required to recapitulate the disease state, including primary hepatocytes, Kupffer cells, and liver endothelial cells.
Our models are ideal for long-term dosing protocols necessary to gauge the effectiveness of novel compounds and may be used for high-throughput screening and drug efficacy testing for the treatment of diet-induced steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis.
Accelerating your NASH discovery using our 3D liver disease models.
Diet-induced Steatosis Model: Lipid-load human liver organoids to mimic the fatty liver phenotype of early-stage non-alcoholic fatty liver disease. Extend your assay window for efficacy testing of anti-steatotic drugs.
NASH Model: Investigate the progression of disease from steatosis to inflammation and fibrosis in the first 3D in vitro human model for NASH. Test efficacy of anti-NASH drugs using InSphero's advanced 3D human liver disease model.
Liver Disease Models
Diet-induced Steatosis Model
Lipid-load human liver microtissues to mimic the fatty liver phenotype of early-stage non-alcoholic fatty liver disease.